Population Pharmacokinetics of Abacavir in Pregnant Women
|
|
- Mabel Pamela McDonald
- 5 years ago
- Views:
Transcription
1 AAC Accepts, published online ahead of print on 28 July 2014 Antimicrob. Agents Chemother. doi: /aac Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 Population Pharmacokinetics of Abacavir in Pregnant Women 2 3 Floris Fauchet a,b (#),PharmD, Jean-Marc Treluyer a,b,c,d, MD, PhD, Laure-Helene Préta a, 4 Elodie Valade, a,b PharmD, Emmanuelle Pannier e, MD, Saik Urien *,a,b,d, MD, PhD, Déborah Hirt *,a,b,c,d, PharmD, PhD a EA 08 Université Paris Descartes, Sorbonne Paris Cité, France ; b Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, Paris, France ; c Service de Pharmacologie Clinique, AP-HP, Groupe Hospitalier Paris Centre, France ; d CIC-0901 Inserm, Cochin-Necker, Paris, France ; e Service de Gynécologie-Obstétrique, Maternité Port Royal, Groupe Hospitalier Paris Centre, *Saik Urien and Deborah Hirt contributed equally as last authors France Corresponding author: Floris Fauchet, Unité de Recherche Clinique, AP-HP, Hôpital Tarnier 89 rue d Assas, Paris, France florisfauchet@gmail.com Running title: ABC Population pharmacokinetics
2 24 Abstract For the first time, a population approach was used to describe abacavir pharmacokinetics in HIV infected pregnant and non-pregnant women. A total of 266 samples were obtained from 150 women. No covariate effect (age, bodyweight, pregnancy, gestational age) was found on abacavir pharmacokinetics. Thus, it seems not necessary to adapt ABC dosing regimen during pregnancy. Short form Paper Abacavir is a potent nucleoside reverse transcriptase inhibitor administered to treat human immunodeficiency virus (HIV) infection and prevent its transmission. Currently, regimens containing abacavir are still recommended as one of the first line options for adults including pregnant women (1). Abacavir pharmacokinetics has been previously investigated in adults (2 9) but only two limited studies (small number of patients, no once daily administration, narrow ranges of age and gestational age) were focused on pregnant women (10, 11). During pregnancy some physiological changes can affect the pharmacokinetics of a drug. Therefore, it is important to characterize these changes in a large population in order to use safely and efficiently the drug during pregnancy. Thus, ABC plasma concentrations in non-pregnant and pregnant women were analyzed using a population approach for the first time. The population pharmacokinetic parameters in HIV infected non-pregnant and pregnant women were estimated and the final model was used to determine if the current recommended doses produce efficient drug exposure in pregnancy.
3 The HIV-infected pregnant (n=36) and non-pregnant women (n=114) were (median [range]) 35.7 [15-67] years old and their body weight was 62.5 [40-102] kg. The gestational age at pharmacokinetic evaluation was 31 [9-41] weeks. A total of 266 samples were obtained from HIV infected women. Among these samples, 16 were collected in pairs (maternal and cord blood). Women received orally an ABC-containing regimen: 300 mg twice daily (47.9 %) or 600 mg once daily (52.1 %). Blood sampling were collected for therapeutic drug monitoring during a visit in the pharmacology unit of Hospital Cochin (Paris, France), therefore the times elapsed between drug administration and sampling times were variable. The pregnant women were enrolled at clinical sites of the ANRS-C01-French Perinatal Cohort (EPF). The mother of the child to be born provided signed informed consent. For the non-pregnant women, ethics committee approval and patient consent are not compulsory in France to use therapeutic drug monitoring data retrospectively. Plasma ABC concentrations were determined by high-performance liquid chromatography, as previously described (12). The limit of quantification (LOQ) was 0.02 mg/liter. Mean inter assay precisions of the lowest concentration of the quality controls was 10 %. The data were analyzed using NONMEM software (version 6.2) and the first order conditional estimation with interaction (FOCEI) method was applied (13). The 23 (8.6 %) concentrations below the LOQ (BLQ) were replaced by the LOQ/2 value (14). Use of the M3 method and the built-in M2 method were also tested for the BLQ data but they did not improve the results (15). A one compartment model with first order absorption and elimination was used to describe the data. The between-subject variability (BSV) could only be estimated for the apparent clearance. The combined model was not significantly better than the proportional model and the additive model was significantly worse than the combined model. Thus the
4 proportional error model was the best to describe the residual variability. The absorption constant (Ka) could not be well estimated, but the stability of the model was improved when the value was fixed to 1.8 h -1, a value reported in adults by Jullien et al (4). No covariate (age, bodyweight, pregnancy, gestational age) had a significant effect on pharmacokinetics. So pregnant women and non-pregnant women had the same median population clearance. This is consistent with the previous studies reporting similar exposures between postpartum or non-pregnant women and pregnant women (10, 11). The final population pharmacokinetic estimates are summarized in Table 1. The stability of the model and accuracy of the parameters were assessed by a bootstrap method implemented in Wings for Nonmem (WfN, This method involves repeated random re-sampling with replacement from the original dataset for 1000 times. The parameters and their associated BSV were accurately estimated, and the confidence intervals (CIs) derived from the bootstrap analysis were reasonably narrow and did not include zero. The model was evaluated by the visual predictive check (VPC)(16) and the normalized prediction distribution errors (NPDE)(17). As confirmed by the VPC in Figure 1, the average prediction matched the observed concentrations and the variability was reasonably estimated. Moreover, the mean and the variance of the NPDE were not significantly different from 0 (p=0.10) and 1 (p=0.66) and the distribution was not different from normal one (p=0.53). The placental transfer during pregnancy was estimated as the median fetal-tomaternal ratio concentrations at delivery. The median [min-max] estimated value was 104% [62%-163%]. This value is similar to those previously described [103%;106 %] (11, 12). We have tried to establish a model to describe fetal concentrations by connecting a
5 peripheral or an effect compartment. However, a successful convergence could not be obtained. This study presents several limits. Pregnant and non pregnant women could be included, allowing abacavir pharmacokinetics comparison between groups; however the number of pregnant women (n=36) was less important that the number of non-pregnant women (n = 114). Moreover this sparse sampling (1 or 2 samples per patient) could have led to a simplified model (one compartment model, fixed ka value) and these data from TDM resulted in a high residual variability. However the bootstraps, VPC and NPDE procedures gave a satisfactory evaluation the model. To conclude, this is the first time that a population approach is used to describe abacavir pharmacokinetics in a large non-pregnant and pregnant women population. No covariate was found to influence abacavir pharmacokinetics, then pregnant and nonpregnant women had similar pharmacokinetics. Thus, it seems not necessary to adapt ABC dosing regimen during pregnancy. References: 1. World Health Organization Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization. 2. Zhao W, Cella M, Della Pasqua O, Burger D, Jacqz-Aigrain E, Pediatric European Network for Treatment of AIDS (PENTA) 15 study group Population pharmacokinetics and maximum a posteriori probability Bayesian
6 estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. Br J Clin Pharmacol 73: Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P, Baker CJ Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 43: Jullien V, Tréluyer J-M, Chappuy H, Dimet J, Rey E, Dupin N, Salmon D, Pons G, Urien S Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. Br J Clin Pharmacol 59: Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN, Craig C, Scott TR, Ziagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study Team Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J. Acquir. Immune Defic. Syndr. 38: DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD, Adult AIDS Clinical Trials Group Protocol 368/886 Study Team Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47: Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W, CNAAB3005 International Study Team Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in
7 antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285: Weller S, Radomski KM, Lou Y, Stein DS Population Pharmacokinetics and Pharmacodynamic Modeling of Abacavir (1592U89) from a Dose-Ranging, Double-Blind, Randomized Monotherapy Trial with Human Immunodeficiency Virus-Infected Subjects. Antimicrob Agents Chemother 44: McDowell JA, Lou Y, Symonds WS, Stein DS Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 44: Mirochnick M, Capparelli E Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 43: Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD, PACTG P1026s Study Team Impact of pregnancy on abacavir pharmacokinetics. AIDS 20: Chappuy H, Tréluyer J-M, Jullien V, Dimet J, Rey E, Fouché M, Firtion G, Pons G, Mandelbrot L Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48: Beal SL, Sheiner LB NONMEM User Guides (I VIII). 14. Beal SL Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:
8 Ahn JE, Karlsson MO, Dunne A, Ludden TM Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35: Post TM, Freijer JI, Ploeger BA, Danhof M Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35: Comets E, Brendel K, Mentré F Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90: Legend: Figure 1: Visual predictive check: comparison between the 5 th (dashed line), 50 th (full line) and 95 th (dashed line) percentiles obtained from 1000 simulations and the ABC observed plasma concentrations (o) in pregnant women (A) and non-pregnant women (B). The model predictions and observations have been normalized to the median ABC dose, 600 mg.
9
10 Table 1 Population pharmacokinetics parameters of ABC from the final model * Pharmacokinetic parameters Estimate RSE 95 % CI Ka (h -1 ) 1.8 ** - - CL/F (L.h -1 ) V/F (L) ω CL/F σ ABC * RSE is the standard error of the estimate divided by the estimate and multiplied by 100. (95%CI are derived from a bootstrap procedure); * *fixed value; ω, square root of between-subject variance; σ, residual variability. Downloaded from on July 12, 2018 by guest
Pregnancy-Related effects on Tenofovir Pharmacokinetics: A Population Study with 186 women.
AAC Accepts, published online ahead of print on 28 November 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.05244-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationDevelopmental Pharmacokinetics of Lamivudine in 580 Pediatric Patients Ranging from Neonates to Adolescents
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3498 3504 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01622-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Developmental
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationPregnancy-Related Effects on Nelfinavir-M8 Pharmacokinetics: a Population Study with 133 Women
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2006, p. 2079 2086 Vol. 50, No. 6 0066-4804/06/$08.00 0 doi:10.1128/aac.01596-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Pregnancy-Related
More informationPhase II clinical trial TEmAA. Didier Koumavi EKOUEVI, MD PhD (Principal Investigator)
The combination of Tenofovir-Emtricitabine (Truvada ): a new antiretroviral (ARV) regimen for the prevention of mother-to-child transmission of HIV-1 (PMTCT) in resource-limited settings Phase II clinical
More informationAntiviral Therapy 2012; 17:25 33 (doi: /IMP1915)
Antiviral Therapy 202; 7:25 33 (doi: 0.385/IMP95) Original article Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
More informationQuinine Pharmacokinetics and Pharmacodynamics in Children with Malaria Caused by Plasmodium falciparum
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2005, p. 3658 3662 Vol. 49, No. 9 0066-4804/05/$08.00 0 doi:10.1128/aac.49.9.3658 3662.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationBritish Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology DOI:1.1111/j.1365-2125.8.3118.x An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and
More informationPlasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2011, p. 5294 5299 Vol. 55, No. 11 0066-4804/11/$12.00 doi:10.1128/aac.05317-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Plasma
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationAge-Related Effects on Nelfinavir and M8 Pharmacokinetics: a Population Study with 182 Children
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2006, p. 910 916 Vol. 50, No. 3 0066-4804/06/$08.00 0 doi:10.1128/aac.50.3.910 916.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationOriginal article Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana
Antiviral Therapy 203; 8:585 590 (doi: 0.385/IMP2474) Original article Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana Roger L Shapiro,2,3
More informationRecommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and
Recommendations for Use of Antiretroviral s in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, June 23, 2004, CDC and updated
More informationReceived 28 May 2011/Returned for modification 16 July 2011/Accepted 14 September 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2011, p. 5529 5540 Vol. 55, No. 12 0066-4804/11/$12.00 doi:10.1128/aac.00741-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Quantifying
More informationRaltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection: IMPAACT P1110
Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection: IMPAACT P1110 Clarke DF, Acosta EP, Chain A, Cababasay M, Wang J, Calabrese K, Spector SA, Bryson
More informationJoint Population Pharmacokinetic Analysis of Zidovudine, Lamivudine, and Their Active Intracellular Metabolites in HIV Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3423 3431 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01487-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Joint
More informationComparing Proportions between Two Independent Populations. John McGready Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationPK/PD modeling and optimization of eltrombopag dose and regimen for treatment of chemotherapy- induced thrombocytopenia in cancer patients
PAGE 2012 PK/PD modeling and optimization of eltrombopag dose and regimen for treatment of chemotherapy- induced thrombocytopenia in cancer patients S. Hayes 1, P. N. Mudd Jr 2, D. Ouellet 2, E. Gibiansky
More informationPopulation Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/ Vilanterol via a Single Inhaler in Patients with COPD
Pharmacometrics Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/ Vilanterol via a Single Inhaler in Patients with COPD The Journal of Clinical Pharmacology 2018, 0(0) 1 7 C 2018,
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationA population pharmacokinetic model for rifampicin auto induction
A population pharmacokinetic model for rifampicin auto induction Paolo Denti 1, Wynand Smythe 1, Ulrika SH Simonsson 2, Roxana Rustomjee 3, Philip Onyebujoh 4, Peter Smith 1, Helen McIlleron 1 1 Division
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationPopulation pharmacokinetic analysis of metformin administered as fixed-dose combination in Korean healthy adults
TCP 2018;26(1):25-31 2018;26(1):01-48 http://dx.doi.org/10.12793/tcp.2018.26.1.25 http://dx.doi.org/10.12793/tcp.2018.26.1.xx Population pharmacokinetic analysis of metformin administered as fixed-dose
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationAntiviral Therapy 2016; 21: (doi: /IMP3001)
Antiviral Therapy ; : (doi:.8/imp) Short communication Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir boosted lopinavir on HIV viral load reduction during
More informationDevelopment and Evaluation of Bayesian Software for Improving Therapeutic Drug Monitoring of Gentamicin in Neonates
Development and Evaluation of Bayesian Software for Improving Therapeutic Drug Monitoring of Gentamicin in Neonates Eva Germovšek, Alison Kent, Nigel Klein, Mark A Turner, Mike Sharland, Elisabet Nielsen,
More informationPopulation Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development. Leon Aarons Manchester Pharmacy School University of Manchester
Population Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development Leon Aarons Manchester Pharmacy School University of Manchester Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics
More informationVisit Reason: Positive Pregnancy Test. HIV Treatment in the Childbearing Woman
Visit Reason: Positive Pregnancy Test. HIV Treatment in the Childbearing Woman Thi-Thi Nguyen, PharmD, BCPS, AAHIVP Mountain Plains AIDS Education and Training Center Conference August 13th, 2015 1 Objectives
More informationAre Children Small Adults?
Are Children Small Adults? What can modeling offer to (clinical) practice? Catherijne Knibbe, PharmD, PhD Hospital Pharmacist-Clinical Pharmacologist How are children dosed in (clinical) practice? In practice
More informationPersistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome
J Antimicrob Chemother 2012; 67: 2231 2235 doi:10.1093/jac/dks191 Advance Access publication 29 May 2012 Persistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationMany highly active antiretroviral therapy PROCEEDINGS
MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: IS THERE A ROLE FOR QUADRUPLE REGIMENS? * François Raffi, MD, PhD ABSTRACT Although many highly active antiretroviral therapy (HAART)
More informationAnakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
Urien et al. BMC Pharmacology and Toxicology 2013, 14:40 RESEARCH ARTICLE Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
More informationModule Summary of Clinical Pharmacology
Module 2.7.2 Summary of Clinical Pharmacology Copyright 2003 the GlaxoSmithKline group of companies. All rights reserved. Unauthorised copying or use of this information is prohibited. 2 TABLE OF CONTENTS
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationHIV and pregnancy: how to manage conflicting recommendations from evidence-based guidelines
OPINION HIV and pregnancy: how to manage conflicting recommendations from evidence-based guidelines Michelle L. Giles a,b In resource rich settings transmission of HIV from mother to child during pregnancy
More informationIgnacio Cortínez Anesthesiology Department School of Medicine, Pontificia Universidad Católica de Chile
Recommended doses of Levobupivacaine for TAP Blocks: Development of a pharmacokinetic model and estimation of the risk of symptoms of local anesthetic systemic toxicity Ignacio Cortínez Anesthesiology
More informationMalaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh
Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Acknowledgement Table of contents Evolution of when to initiate therapy ART improves survival
More informationIndinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2003, p. 1929 1935 Vol. 47, No. 6 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.6.1929 1935.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationInfertility Treatment and HIV
Infertility Treatment and HIV Infertility Treatment by IVF Or Intra-cytoplasmic Sperm Injections (ICSC) In Chronic HIV-1 Sero- discordant Couples (Poster 670) Retrospective study of outcome of IVF or ICSC
More informationPOPULATION PHARMACOKINETICS
POPULATION PHARMACOKINETICS Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development 1 Population Pharmacokinetics Definition Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationANTIRETROVIRAL (ART) DRUG INFORMATION FOR HEALTH CARE PROFESSIONAL
ZIDOVUDINE (AZT, Retrovir ) Benefits of zidovudine: Zidovudine (ZDV) is an antiretroviral drug that slows the growth of the HIV virus. It has shown in a large randomized, multicentre study to decrease
More informationPOPULATION PHARMACOKINETICS. Population Pharmacokinetics. Definition 11/8/2012. Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development.
/8/202 POPULATION PHARMACOKINETICS Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development Population Pharmacokinetics Definition Advantages/Disadvantages Objectives of Population Analyses Impact in Drug
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationCCC ARV Dosing Recommendations for HIV-exposed infants Updated
USERS NOTE: Please note this document does not provide guidance on overall decisionmaking regarding what medication(s) to use for HIV-exposed infants. This document is meant to facilitate ARV dosing for
More informationPharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2008.03220.x Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women Matthieu Roustit, 1,2 Malik Jlaiel, 1
More informationThe Promise of HIV Prevention in Pregnancy. Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA
The Promise of HIV Prevention in Pregnancy Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA Outline Pregnancy/Lactation Brief background Where we were Where we are now Where we are
More informationManagement of the HIV-Exposed Infant
Management of the HIV-Exposed Infant Katherine Knapp, MD Medical Director, Perinatal Program Department of Infectious Diseases St. Jude Children s Research Hospital Disclosures No conflicts of interest
More informationPopulation pharmacokinetics and dosing optimization of vancomycin. in children with malignant hematological disease
AAC Accepts, published online ahead of print on 24 March 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02564-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Population
More informationPopulation pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents
British Journal of Clinical Pharmacology DOI:1.1111/j.1365-2125.211.435.x Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents Frantz Foissac, 1,2 Stéphane Blanche,
More informationPK-PD modelling to support go/no go decisions for a novel gp120 inhibitor
PK-PD modelling to support go/no go decisions for a novel gp120 inhibitor Phylinda LS Chan Pharmacometrics, Pfizer, UK EMA-EFPIA Modelling and Simulation Workshop BOS1 Pharmacometrics Global Clinical Pharmacology
More informationTitle: Cefoxitin Continuous Infusion for Lung Infection Caused by M. abscessus group
AAC Accepts, published online ahead of print on 14 April 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02763-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 Title: Cefoxitin
More informationPediatric ARV Working Group Dosing Recommendations
Pediatric ARV Working Group Dosing Recommendations Overall Goals To develop pediatric weight band dosing for ARVs that would simplify dosing and produce therapeutic drug exposure Recommend dosing strengths
More informationRisk Factors for Detectable HIV-1 RNA at Delivery Among Women Receiving Highly Active Antiretroviral Therapy in the Women...
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/40908390 Risk Factors for Detectable HIV-1 RNA at Delivery Among Women Receiving Highly Active
More informationTB/HIV/STD Epidemiology and Surveillance Branch. First Annual Report, Dated 12/31/2009
TB/HIV/STD Epidemiology and Surveillance Branch First Annual Report, Dated 12/31/29 This Enhanced Perinatal Surveillance Report is the first annual report generated by the Texas Department of State Health
More informationPerinatal HIV Exposure: Antiretroviral Management. Danielle McDonald, PharmD PGY-2 Pediatric Pharmacotherapy Resident
Perinatal HIV Exposure: Antiretroviral Management Danielle McDonald, PharmD PGY-2 Pediatric Pharmacotherapy Resident A presentation for HealthTrust Members June 1, 2018 Learning Objectives for Pharmacists
More informationRisk Management Plan Summary
Risk Management Plan Summary EDURANT (rilpivirine) 25 mg film-coated tablet Document Version: 1.0 Document Date: 30.10.2017 Based on EU RMP version 7.0 Marketing authorization holder: Janssen-Cilag AG,
More informationCourse of Maternal Human Immunodeficiency Virus
Infectious Diseases in Obstetrics and Gynecology 2:251-254 (1995) (C) 1995 Wiley-Liss, Inc. Effect of Successive Single-Gestation Pregnancies on the Course of Maternal Human Immunodeficiency Virus Disease
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationResearch Article. Philippe B. Pierrillas, 1,3,5 Michel Tod, 1,2 Magali Amiel, 3 Marylore Chenel, 4 and Emilie Henin 1
The AAPS Journal, Vol. 18, No. 2, March 2016 ( # 2016) DOI: 10.1208/s12248-015-9862-1 Research Article Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel
More informationAN ATYPICAL JOINT MODEL OF PSA AND CTC COUNT KINETICS DURING TREATMENT IN PROSTATE CANCER
AN ATYPICAL JOINT MODEL OF PSA AND CTC COUNT KINETICS DURING TREATMENT IN PROSTATE CANCER Mélanie Wilbaux, Michel Tod, Johann De Bono, David Lorente, Joaquin Mateo, Gilles Freyer, Benoit You, Emilie Hénin
More informationPharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women
Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women DR MINH LÊ PHARMACO-TOXICOLOGY DEPARTMENT APHP, HÔPITAL BICHAT-CLAUDE BERNARD PARIS, FRANCE ABSTRACT #O_01 17TH INTERNATIONAL
More informationTranslational PK M&S for the assessment of duration of contraceptive cover after use of miltefosine for the treatment of visceral leishmaniasis
Translational PK M&S for the assessment of duration of contraceptive cover after use of miltefosine for the treatment of visceral leishmaniasis Thomas Dorlo, Manica Balasegaram, Nines Lima, Peter de Vries,
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationPharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis
AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics
More informationBaylor-Uganda, Paediatric Infectious Diseases Clinic, Mulago Hospital, Kampala, Uganda 4
Antiviral Therapy 2010; 15:1115 1124 (doi: 10.3851/IMP1695) Original article Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1- infected Ugandan children
More informationPharmacometric Modelling to Support Extrapolation in Regulatory Submissions
Pharmacometric Modelling to Support Extrapolation in Regulatory Submissions Kristin Karlsson, PhD Pharmacometric/Pharmacokinetic assessor Medical Products Agency, Uppsala,Sweden PSI One Day Extrapolation
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPopulation Pharmacokinetics of Tenofovir and Tenofovir-Diphosphate in Healthy Women
Pharmacometrics Population Pharmacokinetics of Tenofovir and Tenofovir-Diphosphate in Healthy Women The Journal of Clinical Pharmacology 2015, 55(6) 629 638 2015 The Authors. The Journal of Clinical Pharmacology
More informationGlobal Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2003, p. 350 359 Vol. 47, No. 1 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.1.350 359.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationA Descriptive Study of Outcomes of Interventions to Prevent Mother to Child Transmission of HIV in Lusaka, Zambia
ORIGINAL PAPER A Descriptive Study of Outcomes of Interventions to Prevent Mother to Child Transmission of HIV in Lusaka, Zambia Chibesa Shichitamba W, National Malaria Control Centre, Lusaka-Zambia ABSTRACT
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationEvidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February For public consultation
Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February 2016 - NHS England Evidence Review: Comparison of tenofovir alafenamide and tenofovir disoproxil fumarate.
More informationReferences: 1. XVI International AIDS Conference, 2006 Abstract no. ThPE0120 2. Bergshoeff A, Burger D, Farrelly L e t al. Pharmacokinetics of once daily vs. twice daily lamivudine and abacavir in HIV-Infected
More informationWhat s New. In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group
What s New In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group Guidelines for our Online Meeting Room You will be listening to
More informationOriginal article A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations
Antiviral Therapy 13:779 787 Original article A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations Rob ter Heine 1 *, Henriette
More informationPopulation pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson s disease
ORIGINAL ARTICLE Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson s disease Luca Loprete 1, Chiara Leuratti 2, Carlo Cattaneo 3, Mita M. Thapar 4, Colm Farrell
More informationModel-based quantification of the relationship between age and anti-migraine therapy
6 Model-based quantification of the relationship between age and anti-migraine therapy HJ Maas, M Danhof, OE Della Pasqua Submitted to BMC. Clin. Pharmacol. Migraine is a neurological disease that affects
More informationA Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients
CMU. J. Nat. Sci. (2012) Vol. 11(1) 77 A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients Yupaporn Preechagoon 1 and Peeraya Somsaard 2* 1 Department
More informationOriginal article Pharmacokinetics, safety and efficacy of ritonavir boosted atazanavir (300/100 mg once daily) in HIV 1-infected pregnant women
Antiviral Therapy 2015; 20:507 513 (doi: 10.3851/IMP2936) Original article Pharmacokinetics, safety and efficacy of ritonavir boosted atazanavir (300/100 mg once daily) in HIV 1-infected pregnant women
More information1 Introduction. Trine Høyer Rose 1,2 Daniel Röshammar. Johnny T. Ottesen 2
Drugs R D (2016) 16:165 172 DOI 10.1007/s40268-016-0126-z ORIGINAL RESEARCH ARTICLE Characterisation of Population Pharmacokinetics and Endogenous Follicle-Stimulating Hormone (FSH) Levels After Multiple
More informationComparing Proportions between Two Independent Populations. John McGready Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationCUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date
CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA 350 300 250 Number 200 150 100 50 0 1/01/1997 1/01/1998 1/01/1999 1/01/2000 31/12/2000 31/12/2001 31/12/2002 Date July 2004 Reported number of perinatally exposed
More informationAn integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers
Title: An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers Authors: Hanna E. Silber 1, Nicolas Frey 2 and Mats O. Karlsson 1 Address: 1 Department of
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationEffect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
AAC Accepts, published online ahead of print on 19 December 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.05739-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. 1 Effect
More informationPREVENT TRANSMISSION OF HIV/AIDS PREGNANT WOMEN : LITERATUR REVIEW
PREVENT TRANSMISSION OF HIV/AIDS PREGNANT WOMEN : LITERATUR REVIEW *Nunung Nurhayati STIKep PPNI Jawa Barat, Bandung, West Java Indonesia Email: nunky_adzra@yahoo.com ABSTRACT Baby risk be infected HIV/AIDS
More informationPlasma and Intracellular Tenofovir Pharmacokinetics in the Neonate (ANRS Trial, Step 2)
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2011, p. 2961 2967 Vol. 55, No. 6 0066-4804/11/$12.00 doi:10.1128/aac.01377-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Plasma
More informationAccording to the Centers for Disease REVIEW HIV MANAGEMENT AND TREATMENT ISSUES DURING PREGNANCY. Billy R. Brown, PharmD * ABSTRACT
HIV MANAGEMENT AND TREATMENT ISSUES DURING PREGNANY illy R. rown, PharmD * ASTRAT Most children with HIV/AIDS acquire the virus from their mothers. The United States Preventive Services Task Force recommends
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationClinical Study Amniocentesis in HIV Pregnant Women: 16 Years of Experience
Hindawi Publishing Corporation Infectious Diseases in Obstetrics and Gynecology Volume 2013, Article ID 914272, 5 pages http://dx.doi.org/10.1155/2013/914272 Clinical Study Amniocentesis in HIV Pregnant
More informationOnce-a-Day Highly Active Antiretroviral Therapy: A Systematic Review
HIV/AIDS MAJOR ARTICLE Once-a-Day Highly Active Antiretroviral Therapy: A Systematic Review Javier Ena and Francisco Pasquau HIV Unit, Department of Internal Medicine, Marina Baixa Hospital, Villajoyosa,
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More information